Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
By Ben Glickman
Sobi North America said it had received fast track designation from U.S. regulators for its potential treatment for Macrophage Activation Syndrome, a complication of rheumatic diseases.
The Waltham, Mass.-based affiliate of Swedish Orphan Biovitrum said Friday that the U.S. Food and Drug Administration had granted the designation to emapalumab-lzsg, a monoclonal antibody. The compound is currently the only medicine approved in the U.S. for primary haemophagocytic lymphohistiocytosis, a syndrome of hyperinflammation also known as HLH, according to Sobi.
MAS, a form of HLH, is characterized by fever, liver dysfunction and other symptoms.
Emapalumab is currently in phase 3 development for treating MAS.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 24, 2024 15:45 ET (19:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks